Rationale: Cyclooxygenase (COX)-derived prostanoids (PGs) are involved in blood pressure homeostasis. Both traditional nonsteroidal antiinflammatory drugs (NSAIDs) that inhibit COX-1 and COX-2 and NSAIDs designed to be selective for inhibition of COX-2 cause sodium retention and elevate blood pressure. Objective: To elucidate the role of COX-2 in blood pressure homeostasis using COX-1>COX-2 mice, in which the COX-1 expression is controlled by COX-2 regulatory elements. Methods and Results: COX-1>COX-2 mice developed systolic hypertension relative to wild types (WTs) on a high-salt diet (HSD); this was attenuated by a PGI 2 receptor agonist. HSD increased expression of COX-2 in WT mice and of COX-1 in COX-1>COX-2 mice in the inner renal medulla. The HSD augmented in all strains urinary prostanoid metabolite excretion, with the exception of the major PGI 2 metabolite that was suppressed on regular chow and unaltered by the HSD in both mutants. Furthermore, inner renal medullary expression of the receptor for PGI 2 , but not for other prostanoids, was depressed by HSD in WT and even more so in both mutant strains. Increasing osmolarity augmented expression of COX-2 in WT renal medullary interstitial cells and again the increase in formation of PGI 2 observed in WTs was suppressed in cells derived from both mutants. Intramedullary infusion of the PGI 2 receptor agonist increased urine volume and sodium excretion in mice. Conclusions: These studies suggest that dysregulated expression of the COX-2 dependent, PGI 2 biosynthesis/ response pathway in the renal inner renal medulla undermines the homeostatic response to a HSD. Inhibition of this pathway may contribute directly to the hypertensive response to NSAIDs. (Circ Res. 2010;106:337-345.)
P rostaglandins contribute to blood pressure (BP) homeostasis via their direct effects on vascular tone and on fluid and electrolyte transport in the kidney. Nonsteroidal antiinflammatory drugs (NSAIDs) block prostanoid (PG) biosynthesis by inhibition of the activity of the cyclooxygenase (COX) isozymes COX-1 and COX-2. 1 Both traditional (t)NSAIDs and those designed to be selective for inhibition of COX-2 may increase systemic BP and/or undermine BP control with antihypertensive drugs. 2, 3 PG formation is generally reactive and elaboration of vasodilator PGs preserves renal blood flow in renoprival conditions. 4 Similarly, NSAIDs, in vulnerable populations, such as the elderly or in response to a hypertensive stimulus, such as a high-salt diet (HSD), decrease total renal perfusion and cause redistribution of renal blood flow. 5 This may lead to medullary ischemia, and even acute renal failure. 6 Even short-term studies of NSAIDs in apparently healthy, but susceptible, populations may result in decreased glomerular filtration rate and urinary sodium retention. 7 In rodents, COX-1 deletion causes natriuresis, accentuates the effects of angiotensin converting enzyme inhibitors, and reduces BP despite activation of the renin-angiotensin system. 8 Indeed, both pharmacological inhibition and genetic deletion of COX-1 abolish the hypertensive response to angiotensin II in mice. 9, 10 Deletion or inhibition of COX-2, by contrast, reduces renal medullary blood flow and sodium excretion, increases the vasoconstrictive response to angiotensin II, 10 and elevates basal BP. 11 These observations have prompted the suggestion that hypertension on NSAIDs is a function of both inhibition of COX-2 and the selectivity with which it is attained. 12 Although this is consistent with some evidence, 3, 13 both the relative importance of selectivity and the mechanism by which COX-2 preserves BP homeostasis remain to be rigorously addressed.
Although the COX isozymes are structurally similar, their method of regulation is quite distinct. 1 One mechanism by which COX-2 might play a role in BP homeostasis is by its ready induction in renal medullary interstitial cells (RMICs) where it is coexpressed with COX-1 14 and induced by high salt or fluid deprivation. 15, 16 Inhibition of medullary COX-2 in rats 17, 18 or global deletion of the PGI 2 receptor (IP) 19, 20 or the EP 2 PGE 2 receptor 21, 22 in mice results in salt-sensitive hypertension. We designed COX-1ϾCOX-2 mice 23 to address the hypothesis that dysregulated expression of COX-2, rather than structural distinctions of COX-2 24 from COX-1, might have relevance to BP homeostasis. Our results support the notion that dysregulated expression of the COX-2 dependent, PGI 2 biosynthesis/response pathway in the renal internal medulla undermines the homeostatic response to a HSD. Inhibition of this pathway may contribute directly to the hypertensive response to NSAIDs.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice
All COX-1ϾCOX-2 and COX-2 null mice used for the experiments were initially produced on a mixed C57BL/6 x Sv129 genetic background (50%:50%). All procedures were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.
BP Measurement
Resting systolic blood was measured in conscious mice using a computerized noninvasive tail cuff system (Visitech Systems Inc) as previously described. 11
Analysis of Renal Medullar Perfusion and Urinary Sodium Excretion
Mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg IM), and the right kidney was removed. After 1 week of recovery, catheters were implanted in the jugular vein, bladder and renal medullary interstitium as described previously. 25 Saline or cicaprost tested compound was infused into the renal medulla at 20 L/h. After 1 hour of equilibration, urine was collected every 30 minutes. Urinary sodium concentration was determined by Electrolyte Analyzer (PL 1000B).
Statistical Analysis
Data are presented as meansϮSEM. Analyses were performed by the ANOVA and subsequent pairwise comparisons as appropriate. A probability value of Ͻ0.05 was considered significant. Prism 4.0 software (GraphPad InStat 3) was used for all the calculations.
Results

COX-1 Rescues the BP and Renin Response to COX-2 Deletion on a Normal Diet but Not on a HSD
COX-2-deficient mice exhibited systolic hypertension (145.0Ϯ5.4 mm Hg versus wild-type [WT] littermates, 122.0Ϯ7.8 mm Hg; PϽ0.01; Figure 1A and Online Figure I ), whereas BP was unaltered in COX-1ϾCOX-2 mice BP (127.0Ϯ5.5 mm Hg versus WT littermates, 123.3Ϯ4.4 mm Hg; Figure 1A ) on a normal chow diet. These results indicate COX-1 could substitute for COX-2 in maintaining BP homeostasis under physiological conditions. This is also consistent with the ability of COX-1 under the COX-2 promoter to rescue impaired renal development, characteristic of COX-2-null mice. 23, 26 The renal cortical hypoplasia and biochemical evidence of renal dysfunction in COX-2 knockouts (KOs) was absent in COX-1ϾCOX-2 mice (Online Figure II) . However, in response to the HSD, COX-1ϾCOX-2 mice developed hypertension (149.7Ϯ7.3 mm Hg versus WT, 128.1Ϯ6.5 mm Hg, PϽ0.05, nϭ9 to 12; Figure 1A ), just like COX-2 KOs (151.0Ϯ 2.9 mm Hg; PϽ0.05). Thus, although COX-1 could rescue the renal developmental impact of COX-2 deficiency, including hypertension on a chow diet, it was unable to compensate for the absence of COX-2 in regulating BP homeostasis in the face of a high salt challenge. Downstream products of COX-2 include renin secretagogues, like PGI 2 . 27, 28 Renin expression was reduced on a chow diet by Ϸ35% in COX-2 KO mice, and this phenotype was rescued in COX-1ϾCOX-2 mice (PϽ0.05; Figure 1B ). However, analogous to the BP response to HSD, the homeostatic decline in renin observed in COX-2 KOs was not rescued in the COX-1ϾCOX-2 mice.
Insertion of COX-1 Does Not Substitute for COX-2-Derived Biosynthesis of PGI 2
We have previously shown in mice and humans that COX-2 is the dominant source of PGI 2 biosynthesis, as measured by its urinary metabolite, 2,3-dinor-6-keto PGF 1␣ (PGIM). 11, 24 By contrast, the major urinary metabolite of PGE 2 , 9,15-dioxo-11␣hydroxy-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGEM), derives from both COX-1 and COX-2. 11 Deletion of COX-2 suppressed both urinary PGIM and PGEM in mice on a chow diet. However, although COX-1 insertion could rescue the decline in PGEM (1.72Ϯ0.38 ng/mg creatinine in COX-2 KO versus 3.15Ϯ0.47 ng/mg creatinine in COX-1ϾCOX-2 versus 3.89Ϯ0.92 ng/mg creatinine in WT) ( Figure 2A) , it had no impact on the suppression of urinary PGIM ( Figure 2B ). A similar disparity in the ability of COX-1 to substitute for COX-2 applied under HSD conditions. HSD increased excretion of all metabolites consistent with induction of COX-2 in renal medulla (see below) in WT mice. Deletion of COX-2 had no impact on excretion of major metabolites of either PGD 2 (11,15-dioxo-9␣-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid) or thromboxane (Tx) (2,3-dinor-TxB 2 ), both of which derive predominantly from COX-1, 29,30 on either chow or HSD ( Figure 2C and 2D).
Medullary COX-1 Expression in Response to HSD in the Absence of COX-2
HSD is recognized to have divergent effects on expression of COXs in kidney. 15 As expected, the HSD had no significant effect on WT COX-1 expression in both cortex and medulla ( Figure 3A and 3C), whereas it downregulated COX-2 expression in cortex and upregulated COX-2 in medulla in WT mice ( Figure 3B and 3D). Indeed, cortical expression of COX-1 tended to be higher in the mutants on regular chow and this change reached significance on a HSD. COX-2 expression was absent, as expected, in both cortex and medulla in the mutants ( Figure 3B and 3D). By contrast, HSD upregulated expression of COX-1 in the cortex of COX-1ϾCOX-2 (760Ϯ30ϫ10 6 /18S rRNA, PϽ0.05) and COX-2 KO versus WT (717Ϯ45ϫ10 6 /18S rRNA versus 503Ϯ34ϫ10 6 /18S rRNA, PϽ0.05) mice ( Figure 3A ) and of COX-1 in the medulla of COX-1ϾCOX-2 (3768Ϯ242ϫ10 6 /18S rRNA versus 2302Ϯ 167ϫ10 6 /18S rRNA, PϽ0.05), whereas it did not regulate expression of medullary COX-1 when the isozyme was expressed under its own promoter ( Figure 3C ). Thus, COX-2 is usually the dominant isoform regulated by HSD in the medulla.
Medullary COX-1 Cannot Restore the COX-2-Dependent Capacity to Generate PGI 2
Given the relevance of COX-2 in the renal medulla to BP homeostasis, 17, 18 the tissue capacity to generate PGs was assessed. This is quite distinct from estimation of systemic PG biosynthesis, as reflected by urinary metabolites; the capacity of tissues to generate PGs greatly exceeds actual synthetic rates in vivo. 31 The most abundant product was PGE 2 (Figure 4 ). Both PGE 2 and PGI 2 (detected as 6-keto-PGF 1␣ ) are vasodilators and PGI 2 is also a potent renin secretagogue. Consistent with hypertension and hyporeninemia ( Figure 1A and 1B) , the capacity to generate these PGs is reduced in COX-2 KOs on a chow diet ( Figure 4A and 4C). By contrast, the rather trivial medullary capacity to generate PGD 2 and PGF 2␣ , both of which derive predominantly from COX-1, is retained ( Figure 4B and 4D) .
HSD augments the capacity to generate renal medullary PGs in WT mice. However, this capacity is attenuated in the case of PGI 2 in both mutant strains ( Figure 4C ). This indicates that COX-2 is the dominant source of this PG and it cannot be substituted for by COX-1 under these conditions. The HSD induced increase in PGE 2 is restrained only in COX-2 KOs, indicating the ability of COX-1 to compensate for COX-2 in the generation of this PG. Given the failure of COX-1 insertion to compensate for the BP effect of deletion of COX-2 ( Figure 1 ), these results implicate PGI 2 as the dominant product of COX-2 restraining the hypertensive response to HSD.
Reduced Expression of the Medullary PGI 2 Receptor on a HSD
Although the EP1 and EP3 receptors for PGE 2 were, by far, the most abundantly expressed in renal medulla, their expression was unaltered in the mutants or by HSD. This was also true for the other receptors for PGE 2 (EP2 and EP4) and also for receptors for PGF 2␣ (the FPs) and for PGD 2 (the DP2). Expression of DP1 was not detectable (Online Figure III) .
Expression of the receptor for TxA 2 , the TP, was suppressed compared to WT by COX-2 deletion on both chow and HSD (Online Figure III) , although this was not evident in the renal cortex (Online Figure IV) , where it is expressed in the glomeruli. 32 Pertinent to its proposed role in the hypertensive response to HSD, medullary expression of the PGI 2 receptor, the IP, is depressed by HSD, even in WT mice and expression of its transcript is detectably further depressed in both mutants ( Figure 5A ). Accordingly, we observed IP protein suppression by HSD was detectable in renal medulla, although no significant difference detected among genotypes ( Figure 5B and 5C ). Thus, decreased expression of the IP could interact with depressed synthesis of PGI 2 in the renal medulla to underlie the hypertensive response to COX-2 deletion and the failure of COX-1 to compensate for this deficiency. A similar pattern of decreased expression of the IP in both mutants on HSD was observed in the renal cortex (Online Figure IV) , where it may be relevant to the attendant hyporeninemia ( Figure 1B ).
IP Receptor Activation Restrains Salt-Induced Hypertension in COX-1>COX-2 Mice
Systemic and renal PGI 2 biosynthesis were impaired under both basal and HSD conditions and renal IP receptor expression was further depressed by HSD in COX-1ϾCOX-2 mice. To examine whether down-regulation of PGI 2 /IP signaling contributes to salt-sensitive hypertension in COX-2 mutant mice, COX-1ϾCOX-2 mice were subcutaneously infused with the IP specific agonist, cicaprost (50 g/kg per day), using an osmotic minipump. BP was recorded before implantation and after exposure to a HSD by tail cuff. Systolic BP in COX-1ϾCOX-2 mice was elevated markedly by the HSD and this effect was significantly attenuated by cicaprost infusion (from 140.8Ϯ4.1 to 119.4Ϯ4.2 mm Hg, PϽ0.01, nϭ9; Online Figure V ).
Differential Substitution of COX-1 for Hypertonic Induction of COX-2-Dependent PG Formation in RMICs
In rodents, COX-2 expression is restricted in RMICs in renal medulla. 14 RMICs were isolated to address the impact of COX-1 substitution for COX-2 in an in vitro model of regulated expression of COX-2. The RMICs derived from COX-2 KOs were hypersensitive to cell dissociation, more than 45% of 3 rd passage COX-2 KO RMICs died when treated with 0.025% trypsin/0.5 mmol/L EDTA compared to less than 3% in cells from either COX-1ϾCOX-2 or WT groups. Unlike the cells from COX-1ϾCOX-2 and WT mice (which passaged for more than 10 generations), even passage 4 RMICs were not derived successfully from COX-2 KO mice. The results are consistent with previous reports that COX-2 plays important role in RMIC survival. 16, 33 Consistent with our analysis of transcripts in the renal medulla of animals on a HSD (Figure 3 ), exposure of RMICs to hypertonic conditions (using addition of NaCl and mannitol to the culture medium) induced expression of COX-2 in WT cells and of COX-1 in those derived from COX-1ϾCOX-2 mice ( Figure 6A ). The capacity of these cells to make PGs was augmented by 630 mOsm/kg H 2 O ( Figure 6B) ; again, PGE 2 is the most abundant product. Although the capacity to form PGI 2 is modest in these cells, induction of its formation is evident. Like PGE 2 , deletion of COX-2 depresses significantly RMIC production of PGI 2 . Substitution of COX-1 for COX-2 in the COX-1ϾCOX-2 mice differentially rescued PG formation under hyperosmolar conditions. Thus, whereas 81%, 75%, and 60% capacity to form PGE 2 , PGD 2 , and PGF 2␣ , respectively, was restored, COX-1 compensated only one-third of the capacity to form PGI 2 (measured as 6-keto-PGF 1␣ ).
Expression of the IP receptor in the renal medulla is largely restricted to the vasa recta. 34, 35 Primary endothelial cells (ECs) and RMICs from same mice were grown in a transwell coculture system to address the possibility of paracrine signaling from RMICs via endothelial IPs. RMICs in the transwell insert were preincubated in media of high osmolality (630 mOsm/kg H 2 O) to induce COX-2 expression, and intracellular cAMP (as a surrogate measure of IP activation) was quantified in ECs grown in the bottom chamber. Again, all PGs released from RMICs from WT in the coculture medium were augmented significantly by hypertonic stress. COX-1 replacement failed to recapitulate PGI 2 induction (measured as 6-keto-PGF 1␣ ) in RMICs from COX-1ϾCOX-2 mice (Online Figure VI, A) . Correspondingly, cAMP production of WT ECs was increased by 2.8-fold in response to stressed RMICs (from 3.6Ϯ0.27 to 9.8Ϯ1.48 pmol/10 5 cells, nϭ6; Online Figure VI, B) , whereas only minimal cAMP in ECs from COX-1ϾCOX-2 mice was detected (0.22Ϯ0.01 to 0.25Ϯ0.03 pmol/10 5 cells; Online Figure VI, B) , and that was not increased by high osmolality. The cAMP response of ECs to cicaprost, did not differ between WT and mutant mice, demonstrating the capacity of the IP to generate the measured signal. These observations are consistent with aberrant IP receptor signaling in the vasa recta in COX-1ϾCOX-2 mice.
Natriuresis Evoked by Activation of the Renal Medullary IP Receptor
The IP agonist cicaprost (10 ng/20 L per hour) significantly and progressively increased urine volume from 0.69Ϯ0.09 L/min (basal level, before infusion) to 1.67Ϯ0.10 L/min (PϽ0.01; Figure 7A ) and urinary sodium excretion from 0.095Ϯ0.002 Eq/min (basal level) to 0.1688Ϯ0.005 Eq/ min (PϽ0.01; Figure 7B ) over 2 hours of direct intramedullary infusion. In contrast, no significant effects on urine volume were observed over the same period during infusion of vehicle control (0.67Ϯ0.12 L/min versus 0.74Ϯ0.05 L/min, PϭNS, nϭ4). Thus, activation of the renal medullary IP is capable of evoking natriuresis.
Discussion
Both tNSAIDs and NSAIDs purposefully developed to inhibit selectively COX-2 (pdNSAIDs) can elevate BP. 3 Vaso- dilator PGs, such as PGI 2 and PGE 2 , are critical to the preservation of renal blood flow in renoprival conditions 4, 25 and COX-2 is the dominant source of biosynthesis of PGI 2 , as assessed by excretion of its major urinary metabolite in humans and in mice. 11, 36 Deletion of the IP results in salt-sensitive hypertension 19, 20 and an increased sensitivity to thrombogenic stimuli, 11 whereas mutations of the IP and PGI 2 synthase have been associated with hypertension and cardiovascular events in humans. 37, 38 Both COX-2 and COX-1 contribute to PGE 2 formation 11 and deletion of at least one of the EPs (the EP2) coupled, like the IP, to adenylate cyclase activation, 34 also results in salt-sensitive hypertension. 21, 22 By contrast, activation of other PGE 2 receptors (EP1 and EP3) elevates BP 39, 40 and activates platelets, 41 respectively, in rodents. Thus, PGI 2 and PGE 2 differ with respect to their relative derivation from COX-2 and their receptor dependent impact on cardiovascular function. Deletion and pharmacological inhibition of the COX isozymes suggests that their products have opposite effects on BP, 10 just as in hemostasis 3 ; thus, the likelihood of a hypertensive response to any NSAID may relate both to inhibition of COX-2 and the selectivity with which it is attained. 12 Large scale clinical trials to address this hypothesis have not been performed. An overview analysis of 19 trials suggested that hypertension was more likely with pdNSAIDs than tNSAIDs. However, these trials were small and heterogeneous with respect to both groups of NSAIDs. Also, many tNSAIDs, such as diclofenac and meloxicam, are similarly selective to the pdNSAID celecoxib for inhibition of COX-2. 42 The COX isozymes differ quite dramatically with respect to their transcriptional regulation. 1 These COX-1ϾCOX-2 mice 23 permit assessment of whether harmonization of regulatory control allows rescue of COX-2 deficiency by COX-1. Our results suggest that COX-2 plays a unique role in maintaining BP homeostasis and that this relates to its preferential linkage to biosynthesis of renal medullary PGI 2 .
The hypertensive response to NSAIDs is quite heterogeneous in humans 43 and is markedly influenced by genetic strain in mice. 44 The precise genetic modifiers of this response remain to be identified. Here we studied mice on a mixed C57BL/6 x Sv129 background, that exhibit hypertension after pharmacological inhibition or genetic deletion of COX-2 when maintained on regular chow. 11 COX-2 plays important roles in development 26 and mice deficient in COX-2 typically exhibit renal hypoplasia and biochemical evidence of renal compromise. Here, COX-1 can rescue the developmental effects, hypertension and hyporeninemia of COX-2 KOs under such physiological conditions. By contrast, COX-1 was unable to compensate for the impact of COX-2 deletion when the mice were exposed to the hypertensive stimulus of a HSD.
This response to a HSD reflects a selective impact on the medullary COX-2/PGI 2 biosynthetic/response pathway that mediates natriuresis. Evidence in the present study suggesting that COX-2 is uniquely coupled to synthesis of PGI 2 derives from metabolite measurement in vivo and estimates of the capacity to generate PGs in both kidney medulla and RMICs. Previous observations that PGI 2 was preferentially produced through COX-2 in macrophages, 45 ECs, 46 and COX/PGI synthase cotransfected HEK293 cells 47 are also consistent with this notion. COX-1 cannot compensate for the failure to augment PGI 2 formation in response to a HSD. This effect is likely amplified by the unexpected depression by the HSD of IP transcript and protein, uniquely among the PG receptors. Indeed, COX-2 deficiency in the mutant mice may have further augmented this effect, attaining significance at the level of IP mRNA.
Renal medullary COX-2 has previously been implicated in buffering the hypertensive response to dietary salt intake. 17, 18 Both COX isoforms are abundant in medulla, but they are distributed differentially. COX-1 is expressed in both the medullary collecting duct and in RMICs. 10, 14, 15 COX-2 is most prominent in RMICs, which are involved in the maintenance of the medullary microcirculation and urinary salt excretion. 10 Although the renal papilla receives less than 1% of total renal blood flow, primarily through the descending vasa recta, 48 medullary blood flow promotes renal salt excretion, so called pressure natriuresis. 48 Deletion of either the IP 19, 20 or EP2 receptors 21, 22 results in salt-sensitive hypertension, whereas deletion of the EP1 40 and PGF 2␣ receptor (FP) 49 reduces BP. IP receptors are expressed abundantly in the renal vasculature. IPs in the vasa recta 34, 35 can indirectly modulate sodium reabsorption by altering blood flow to the adjacent medullary thick ascending limbs and collecting ducts. 50, 51 Expression of the EP2 is also evident in the vasa recta, 52 where it too plays an important role in maintaining fluid and electrolyte balance and BP. 21, 22, 25 Indeed, PGE 2 is the most abundant PG product in the measurements of biosynthetic capacity in renal medulla and RMICs. However, unlike PGI 2 , both systemic and renal medullary synthesis of PGE 2 can be rescued by COX-1 and rescue of PGE 2 is much more efficient than of PGI 2 in RMICs. Thus, PGI 2 is the COX-2 product more directly implicated in the preservation of BP homeostasis in response to dietary salt.
Placebo-controlled trials have revealed a cardiovascular hazard attributable to pdNSAIDs. 3 Although a predisposition to thrombosis is dominant, hypertension and cardiac failure are also evident in the spectrum of this cardiovascular risk. 53 Multiple lines of evidence suggest that the risk of thrombosis is attributable to suppression of COX-2 dependent PGI 2 . 24, 54 The present results integrate this mechanism with a predisposition to hypertension and provide in vivo evidence to support the notion that COX-2 is preferentially coupled to biosynthesis of PGI 2 .
In summary, these results suggest that dysregulated expression of the COX-2-dependent, PGI 2 biosynthesis/response pathway in the renal internal medulla undermines the homeostatic response of BP to a HSD. Inhibition of this pathway may contribute directly to the hypertensive response to both pdNSAIDs and tNSAIDs in humans. Disclosures G.A.F. is a consultant to Logical Therapeutics, receives support for an investigator initiated study from Crystal Genomics and serves of the scientific advisory board of Nicox; both of these companies have an interest in NSAIDs.
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